Dana-Farber
Cancer Centers Nudge Oncologists Toward DPYD Testing as PGx Supporters Push For Guidelines Change
Premium
Several institutions, swayed by PGx experts and advocates, are setting up DPYD testing to avoid deadly chemo toxicities in patients even though the NCCN and FDA don't back it.
New Data Suggests Liquid Biopsy Provides Early ID of Breast Cancer Patients Destined to Recur
Premium
Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.
In Brief This Week: MDxHealth, Co-Diagnostics, HTG Molecular Diagnostics, Immunovia, and More
News items for the in vitro diagnostics industry for the week of Nov. 8, 2021.
In Brief This Week: Foundation Medicine, Myriad Genetics, Immunovia, Biocept, and More
News items for the in vitro diagnostics industry for the week of June 28, 2021.
In Brief This Week: Quest Diagnostics, Biodexis, Caris Life Sciences, SkylineDx, and More
News items for the in vitro diagnostics industry for the week of Feb. 15, 2021.
Jul 6, 2018
Nov 9, 2017